Jaguar Health, Inc. (JAGX): Entry into a Material Definitive Agreement
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001585608 0001585608 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
How this was made
The 30-second read
Why it matters
The manufacturing/supply amendment clarifies inventory title transfer and who manages inventory during a transition period, while Woodward assumes certain costs/liabilities. Separately, the optional conversion sets a specific conversion ratio and an effective time, which can shift dilution expectations and short-term trading flows.
Market read
Traders should focus on the fixed preferred-to-common conversion ratio and effective time, plus whether the supply transition reduces operational risk during licensing/operational handoffs.
What to watch
The filing does not quantify dilution magnitude beyond the fixed conversion ratio, nor does it disclose the size of Series O outstanding or any resulting share count—those details will drive the real market impact.
Background
Jaguar Health filed an 8-K covering a manufacturing/supply agreement amendment via its wholly owned subsidiary Napo, plus an optional conversion of Series O convertible preferred into common stock.
Ticker impact
Jaguar’s Napo entered a first amendment to its manufacturing/supply agreement and Jaguar disclosed an optional conversion of Series O preferred into voting common stock.
Likely modest volatility around conversion/dilution expectations; direction depends on whether traders view the conversion as manageable vs dilutive and whether the supply transition reduces operational risk.
The filing is a primary disclosure (8-K) with concrete corporate actions (conversion ratio and timing) and contract amendment terms, but it lacks deal size, financial impact, or guidance numbers to anchor a large repricing.
Market effects
May be read as incremental operational-risk management in specialty pharma supply chains, but no clear sector-wide signal is provided.
Primarily affects US small-cap biotech sentiment; no explicit regional macro linkage.
No direct global supply disruption or international regulatory action is described beyond a Puerto Rico-based counterparty.
Counterpoint
Traders may discount the supply amendment as administrative/transition-only and view the preferred conversion as a scheduled capital-structure event rather than a new funding overhang.
Key entities
- public_companyJaguar Health, Inc.
Nasdaq-listed company filing the 8-K; subject of the optional conversion and supply agreement amendment.
- subsidiaryNapo Pharmaceuticals, Inc.
Wholly owned subsidiary of Jaguar that entered the first amendment with Woodward.
- counterpartyWoodward Specialty LLC
Puerto Rico-based LLC that amended the manufacturing and supply agreement and assumes certain transition costs/liabilities.
